AEON Biopharma, Inc. is a biopharmaceutical company. It engages in the business of developing proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Irvine, CA.
相关临床试验
4
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
3
75.0%
Enrolling By Invitation
1
25.0%
暂无批准数据
- AEON Biopharma announced two complementary transactions totaling up to $22 million in potential proceeds to strengthen its balance sheet and eliminate over 90% of outstanding debt. - The funding includes a $6 million private placement with existing investors and a convertible note exchange with strategic partner Daewoong Pharmaceutical worth $15 million plus accrued interest. - The capital will support uninterrupted advancement of AEON's ABP-450 biosimilar program following positive analytical data submission to the FDA and ahead of an upcoming Type 2a meeting. - ABP-450 is being developed as a biosimilar to BOTOX for therapeutic indications in the U.S. market, which exceeds $3.0 billion annually.
- AEON Biopharma reported 100% amino acid sequence identity between its ABP-450 biosimilar candidate and BOTOX, based on analysis of over 3,400 peptides across multiple lots. - Functional assays demonstrated highly similar potency and composition between ABP-450 and BOTOX across multiple analytical methods, supporting clinical dose predictability. - The company has scheduled an FDA Type 2a meeting for November 19, 2025, to discuss its analytical package and advance toward potential full-label therapeutic biosimilar approval. - ABP-450 is already approved in 69 countries and could become the first full-label therapeutic BOTOX biosimilar in the U.S., targeting a market exceeding $3 billion annually.
- AEON Biopharma has appointed industry veteran Rob Bancroft as Chief Executive Officer to lead the company's development of ABP-450 for therapeutic applications. - ABP-450 (prabotulinumtoxinA) is the same botulinum toxin complex marketed for cosmetic use as Jeuveau, with AEON focusing on its potential for debilitating medical conditions in neurosciences. - The company is pursuing a 351(k) biosimilar pathway with the FDA, aiming to position ABP-450 as a biosimilar to BOTOX for both current and future therapeutic indications.
- The cervical dystonia therapeutics market is poised for growth, driven by advancements in R&D and the emergence of novel treatment options. - Key pipeline drugs, including Daxibotulinumtoxin A from Revance Therapeutics and ABP-450 from AEON Biopharma, are expected to enter the market soon. - Current treatments focus on symptom management, but new therapies aim to address the underlying disease mechanisms for improved outcomes. - Several companies, including Ipsen and Allergan, are actively involved in developing innovative medications and devices for cervical dystonia.
- AEON Biopharma is aligned with the FDA on the 351(k) regulatory pathway for ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA). - Comparative analytical studies are scheduled to begin in Q4 2024 to demonstrate biosimilarity between ABP-450 and BOTOX®. - A Biosimilar Biological Product Development (BPD) Type 2 meeting with the FDA is planned for 2025 to review study results. - AEON aims for a single approval to market prabotulinumtoxinA for all of BOTOX's approved and future therapeutic indications in the U.S.
